| Name | Title | Contact Details |
|---|
ONC Solutions is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Exo (pronounced “Echo”) is pioneering a high-performance handheld ultrasound platform and AI for imaging and therapeutic applications.
Biotronik is a leader in cardio- and endovascular medical technology (pacemakers, implantable defibrillators, stents and remote patient management). We put our heart in it. From its headquarters in Berlin, Germany, BIOTRONIK operates in more than 100 countries around the world, offering products and services essential to the lives of people living with cardiac conditions. BIOTRONIK employs highly committed employees who undertake tenacious research and development and meticulous manufacturing to meet this huge responsibility. BIOTRONIK´s products are designed, produced and sold by people who put their hearts into their work. Quality in every detail. From the very start, BIOTRONIK dedicated itself to driving progress and innovation and delivering exceptional quality. We have earned the trust of medical professionals and patients by combining the renowned art of German engineering with technical excellence and uncompromising quality standards. This dedication is evident in everything we do. High achievers are welcome. Medical engineering is an industry of the future. In a field marked by rapid developments and short innovation cycles, the best guarantees for sustainable success are committed, creative, team-oriented specialists, and outstanding leadership. If you are passionate about computer science, engineering or the natural sciences and enjoy developing new ideas, you´ve found the right place.
Quincy Lab is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1998, REVA Medical is dedicated to developing minimally invasive medical devices that leverage its proprietary biomaterial and stent technologies to improve the treatment of coronary artery disease. Guided by an executive management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA’s initial focus is the development of a drug-eluting bioresorbable coronary scaffold to advance the treatment of cardiovascular disease, the leading cause of death worldwide.